FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the...
The new RSV vaccines for older adults - Mayo Clinic Press
WEBSep 19, 2023 · Arexvy: GSK’s RSV vaccine. Let’s start with GSK’s Arexvy. A study of 24,966 participants showed that Arexvy had an overall efficacy of 82.6% in preventing lower respiratory tract disease — such as pneumonia — caused by RSV.
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older. Late-stage RSV vaccine trials show 'exciting...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s AREXVY, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time.
GSK Announces Positive Topline Data on Co-Administration of AREXVY …
WEBSep 18, 2024 · These data advance the science of co-administration of recommended adult vaccines. PHILADELPHIA, September 18, 2024 -- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus ...
US FDA approves expanded age indication for GSK’s AREXVY, the …
WEBJun 7, 2024 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk.
GSK announces AREXVY, its respiratory syncytial virus (RSV) vaccine…
WEBAug 17, 2023 · AREXVY was approved by the US Food and Drug Administration (FDA) on May 3rd, 2023, for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 60 and older. It was the world’s first vaccine for RSV for older adults, a common, contagious …
GSK Announces Positive Topline Data on Co-Administration of AREXVY …
WEB6 days ago · Indication for AREXVY AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: Individuals 60 years of age and older; ... BioSpace is the digital hub for life science news and jobs. We …
ACIP Evidence to Recommendations for Use of Protein Subunit …
WEBSep 5, 2024 · On May 3, 2023, the Food and Drug Administration (FDA) approved GSK's Arexvy for prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged ≥60 years. 1 Arexvy is a 1-dose (0.5 mL) subunit vaccine containing stabilized RSV prefusion F protein in combination with adjuvant (AS01 E). 1
RSV Vaccine Arexvy Approved for Adults Aged 50 to 59 Years at …
WEBJun 11, 2024 · The Food and Drug Administration (FDA) has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk for RSV disease.
- Some results have been removed